Shipping to United States We Offer Worldwide Shipping
Login Wishlist

syrosingopine

$400

  • Brand : BIOFRON

  • Catalogue Number : BN-O1868

  • Specification : 98%(HPLC)

  • CAS number : 84-36-6

  • Formula : C35H42N2O11

  • Molecular Weight : 666.71

  • PUBCHEM ID : 6769

  • Volume : 20mg

In stock

Quantity
Checkout Bulk Order?

Catalogue Number

BN-O1868

Analysis Method

HPLC,NMR,MS

Specification

98%(HPLC)

Storage

-20℃

Molecular Weight

666.71

Appearance

Powder

Botanical Source

This product is isolated and purified from the roots of Rauvolfia yunnanensis Tsiang

Structure Type

Alkaloids

Category

SMILES

CCOC(=O)OC1=C(C=C(C=C1OC)C(=O)OC2CC3CN4CCC5=C(C4CC3C(C2OC)C(=O)OC)NC6=C5C=CC(=C6)OC)OC

Synonyms

methyl (1R,15S,17R,18R,19S,20S)-17-(4-ethoxycarbonyloxy-3,5-dimethoxybenzoyl)oxy-6,18-dimethoxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate

IUPAC Name

methyl (1R,15S,17R,18R,19S,20S)-17-(4-ethoxycarbonyloxy-3,5-dimethoxybenzoyl)oxy-6,18-dimethoxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate

Applications

Density

1.35g/cm3

Solubility

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

434.6ºC

Boiling Point

795ºC at 760 mmHg

Melting Point

175ºC

InChl

InChI=1S/C35H42N2O11/c1-7-46-35(40)48-31-26(42-3)12-18(13-27(31)43-4)33(38)47-28-14-19-17-37-11-10-22-21-9-8-20(41-2)15-24(21)36-30(22)25(37)16-23(19)29(32(28)44-5)34(39)45-6/h8-9,12-13,15,19,23,25,28-29,32,36H,7,10-11,14,16-17H2,1-6H3/t19-,23+,25-,28-,29+,32+/m1/s1

InChl Key

ZCDNRPPFBQDQHR-SSYATKPKSA-N

WGK Germany

RID/ADR

HS Code Reference

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:84-36-6) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

31746590

Title

Label-Free Proteome Profiling as a Quantitative Target Identification Technique for Bioactive Small Molecules

Author

Kyung Tae Hong 1 2, Jun-Seok Lee 1 2

Publish date

2020 Jan 28

PMID

31431761

Abstract

Objective: To assess the diagnostic value of video-assisted thoracoscopic surgery in exudative pleural effusions, and to evaluated the frequency of malignancy development with long term follow-up of patients defined as nonspecific pleuritis after surgery. .

Methods: The retrospective study was conducted at Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, Turkey, and comprised data of patients with undiagnosed exudative pleural effusions seen between January 2008 and December 2013. Data related to clinical, radiological, thoracoscopical, histopathological and follow-up periods were obtained from the hospital records. SPSS 15 was used for data analysis.

Results: Of the 229 patients, 145(63.3%) were males and 84(36.7%) were females. The overall mean age was 54.5 }15.1 years. Malignancy was found in 84 (36.6%) patients, and tuberculosis in 26(11.4%). The remaining 119(52%) patients had nonspecific pleuritis and their mean follow-up period was 29.2}27.1 months (range: 1-103 months). Video-assisted thoracoscopic surgery was repeated in 3(2.52%) patients in the 1st, 4th and 16th months of followup period due to the recurrence of pleural effusion. Tuberculosis and mesothelioma were diagnosed in 1(0.8%) and 2(1.7%) cases, respectively.

Conclusions: Video-assisted thoracoscopic surgery was found to be a valuable diagnostic procedure in patients with undiagnosed exudative pleural effusion.

KEYWORDS

Video-assisted thoracoscopic surgery, Nonspecific pleuritis, Exudative, Pleural effusion, Follow-up.

Title

The diagnostic role of video-assisted thoracoscopic surgery in exudative pleural effusion and follow-up results in patients with nonspecific pleuritis

Author

Funda Secik Arkin 1, Ali Cevat Kutluk 2, Didem Gorgun 1, Levent Cansever 2, Celalettin Kocaturk 2, Pinar Yildiz 1, Mehmet Ali Bedirhan 2

Publish date

2019 Aug

PMID

30540938

Abstract

Highly glycolytic cancer cells prevent intracellular acidification by excreting the glycolytic end-products lactate and H+ via the monocarboxylate transporters 1 (MCT1) and 4 (MCT4). We report that syrosingopine, an anti-hypertensive drug, is a dual MCT1 and MCT4 inhibitor (with 60-fold higher potency on MCT4) that prevents lactate and H+ efflux. Syrosingopine elicits synthetic lethality with metformin, an inhibitor of mitochondrial NADH dehydrogenase. NAD+, required for the ATP-generating steps of glycolysis, is regenerated from NADH by mitochondrial NADH dehydrogenase or lactate dehydrogenase. Syrosingopine treatment leads to high intracellular lactate levels and thereby end-product inhibition of lactate dehydrogenase. The loss of NAD+ regeneration capacity due to combined metformin and syrosingopine treatment results in glycolytic blockade, leading to ATP depletion and cell death. Accordingly, ATP levels can be partly restored by exogenously provided NAD+, the NAD precursor nicotinamide mononucleotide (NMN), or vitamin K2. Thus, pharmacological inhibition of MCT1 and MCT4 combined with metformin treatment is a potential cancer therapy.

KEYWORDS

MCT1; MCT4; cancer; lactate; metformin; synthetic lethality; syrosingopine.

Title

Dual Inhibition of the Lactate Transporters MCT1 and MCT4 Is Synthetic Lethal with Metformin due to NAD+ Depletion in Cancer Cells

Author

Don Benjamin 1, Dimitri Robay 2, Sravanth K Hindupur 1, Jens Pohlmann 2, Marco Colombi 1, Mahmoud Y El-Shemerly 2, Sauveur-Michel Maira 2, Christoph Moroni 1, Heidi A Lane 3, Michael N Hall 4

Publish date

2018 Dec 11;